CraniUS Therapeutics Closes $20 Million Series B Round to Advance NeuroPASS™ Platform Towards Future Commercialization
Enabling Direct Therapeutic Access Beyond the Blood-Brain Barrier BALTIMORE, Jan. 28, 2026 /PRNewswire/ -- CraniUS Therapeutics LLC, a privately held neurotechnology...
Read moreDetails